Somnomed Limited (AU:SOM)
ASX:SOM
Want to see AU:SOM full AI Analyst Report?
SOM Stock Chart & Stats
AU$0.56
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.56
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.50 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$129.26M
Enterprise ValueAU$121.95M
Total Cash (Recent Filing)AU$18.03M
Total Debt (Recent Filing)AU$14.01M
Price to Earnings (P/E)―
Beta1.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside78.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSustained top-line growth indicates expanding adoption of SomnoMed's oral appliance therapy across markets. Durable revenue expansion supports higher unit volumes, operational scaling and channel investment over the next 2-6 months, reducing execution risk while the company converts clinician interest into orders.
High Gross MarginsA ~60% gross margin denotes attractive unit economics for custom mandibular devices, enabling operating leverage as sales rise. Sustained margins give flexibility to fund R&D, marketing and clinician training, and help absorb SG&A while management pursues scale and improved operating profitability.
Improved Cash GenerationA large improvement in free cash flow and positive operating cash flow despite accounting losses signals stronger cash conversion from core operations. This durable cash generation reduces near-term refinancing pressure, supports reinvestment and provides a buffer for executing growth initiatives.
Bears Say
Persistent Profitability ShortfallOngoing negative net profit and EBIT margins mean SomnoMed has yet to translate revenue and gross-margin strength into sustainable operating profits. Over several months this can limit reinvestment, necessitate cost control or external capital, and increases reliance on execution to reach break-even.
Negative Return On EquityA negative ROE indicates capital is not producing positive shareholder returns, reflecting persistent losses or inefficient capital allocation. This structural weakness can constrain investor support and make future equity raises or growth investments more dilutive or costly over the medium term.
Per-Device Revenue Model ConcentrationSomnoMed's pay-per-device model sold via dental practitioners creates limited built-in recurring revenue and ties growth to clinician adoption and treatment volumes. This structure makes revenue less predictable and scaling more dependent on expanding provider networks and patient throughput over the coming months.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.50 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$129.26M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,083,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (78.57% Upside)
AU$1.00 (78.57% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, in conjunction with its subsidiary companies, specializes in the development and global distribution of oral devices engineered to treat various sleep-related conditions. These essential products are marketed across Europe, North America, and the Asia Pacific region. Its diverse portfolio encompasses the SomnoDent oral appliance, a solution for obstructive sleep apnea; SomnoBrux, a protective dental guard combating damage from teeth grinding; the SomMorning Repositioner, crafted to return the mandible to its initial centric alignment; and SomTabs, cleaning tablets for oral devices. Established in 1987, the company maintains its principal office in Crows Nest, Australia.
SOM Company Deck
SOM Earnings Call
Q2 2026
0:00 / 0:00
SOM Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(78.57% Upside)
Technical Analysis
Options Prices
Currently, No data available
---